• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Hoerter Steven L.

    6/6/25 8:59:30 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hoerter Steven L.

    (Last) (First) (Middle)
    C/O MBX BIOSCIENCES INC.
    11711 N. MERIDIAN STREET, SUITE 300

    (Street)
    CARMEL IN 46032

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MBX Biosciences, Inc. [ MBX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock option (right to buy) $11.86 06/05/2025 A 16,000 (1) 06/05/2035 Common Stock 16,000 $0 16,000 D
    Explanation of Responses:
    1. The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
    /s/ Richard Bartram, attorney-in-fact 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MBX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    10/8/2024$44.00Buy
    Guggenheim
    10/8/2024$40.00Buy
    Stifel
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$30.00Overweight
    JP Morgan
    More analyst ratings

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on MBX Biosciences with a new price target

      Citizens JMP initiated coverage of MBX Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

      4/10/25 12:42:19 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on MBX Biosciences with a new price target

      Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on MBX Biosciences with a new price target

      Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00

      10/8/24 7:30:45 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pescovitz Ora H. bought $45,312 worth of shares (7,693 units at $5.89), increasing direct ownership by 46% to 24,329 units (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      4/10/25 8:39:55 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gordon Carl L bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:56:33 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $2,020,756 worth of shares (190,672 units at $10.60) (SEC Form 4)

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      2/19/25 5:52:03 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mathers Edward T

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      6/6/25 11:29:01 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoerter Steven L.

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      6/6/25 8:59:30 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aynechi Tiba

      4 - MBX Biosciences, Inc. (0001776111) (Issuer)

      6/6/25 8:05:48 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

      CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. "Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of lea

      6/23/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

      GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX's novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MBX 4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GI

      6/16/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

      CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced presentations at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20-23. 2025, Chicago, IL. 846-P - Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers: A Phase 1 Randomized TrialPresenter: Elisa Fabbrini, MD. PhD. Session: General Poster SessionDate: Sunday June 22nd, 2025 Time 12:30-1:30pm CT845-P - M

      6/10/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    SEC Filings

    See more
    • MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      6/16/25 8:02:57 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      6/9/25 7:59:27 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - MBX Biosciences, Inc. (0001776111) (Filer)

      6/6/25 7:59:29 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/8/24 10:52:39 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MBX Biosciences Inc.

      SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

      11/1/24 5:38:56 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MBX Biosciences Inc.

      SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

      9/23/24 6:07:21 PM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    See more
    • MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

      CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. "Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of lea

      6/23/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate

      5/12/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

      CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. "I am thrilled to welcome Steve Hoerter to the Company's Board as an independent director," said Kent Hawryluk, President and Chief

      4/7/25 8:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBX
    Financials

    Live finance-specific insights

    See more
    • MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

      Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

      1/7/25 7:00:00 AM ET
      $MBX
      Biotechnology: Pharmaceutical Preparations
      Health Care